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INTRODUCTION: Interleukin-10 (IL-10) is an anti-
inflammatory cytokine, which active form is a non-
covalent homodimer with two intramolecular disulphide 
bonds that are essential to its biological activity, which 
includes reduction of tumor necrosis factor α (TNF-α) 
synthesis and down-regulation of class II major 
histocompatibility complex (MCH-II) molecules on 
monocytes/macrophages [1]. Due to IL-10 potential 
applications in various medical fields, it is essential to 
develop systems that can effectively deliver the protein. 
A promising system is protein encapsulation by 
polymeric nanopartices (NPs), which minimize 
denaturation, and enables slow-release, while 
maintaining an effective concentration for the necessary 
period of time. In previous work, we have developed 
and characterized NPs obtained by self-assembling of 
hydrophobized dextrin [2] whose properties makes them 
promising for IL-10 delivery.  
METHODS: The recombinant mutated (C149Y) 
murine IL-10 (rIL-10) was expressed, in form of 
inclusion bodies, in E. coli BL21 star. rIL-10 was 
recovered by a process of solubilization in 6M 
guanidine, renaturation and re-oxidation of disulphides. 
The dimeric form of rIL-10 was collected by gel 
filtration and further purified by ion-exchange 
chromatography. SDS-PAGE analysis was used to 
confirm molecular weight and purity. The amount of 
rIL-10 obtained was quantified by ELISA. 
rIL-10 bioactivity was assayed by its ability to inhibit 
the production of TNF-α, quantified by ELISA, and the 
surface expression of MHC-II molecules, monitorized 
by FACS analysis, in lipopolysacharide (LPS) and IFN-
γ activated bone marrow derived macrophages 
(BMDM). 
To form the self-assembled NPs, lyophilized dextrin-
VMA-SC16 was resuspended in culture medium, at 
room temperature. NPs formation was confirmed by 
dynamic light scattering. The complex NPs/rIL-10 was 
formed by dissolving rIL-10 in culture medium and then 
by mixing lyophilized dextrin-VMA-SC16. rIL-10 
incorporation into NPs was verified quantifying the 
amount of rIL-10 free in solution by ELISA. The release 
of rIL-10 from the complex NPs/rIL-10 was assessed in 
a BMDM culture, by measuring free rIL-10 by ELISA. 
Bioactivity of rIL- 
10 released form the NPs/rIL-10 complex was assayed 
as described previously. 
RESULTS: SDS-PAGE confirmed the expression and 
molecular weight (18 kDa) of the rIL-10 as well as their 
purity. Total recovery of dimeric rIL-10 was about 1-1.5 
mg/L culture, quantified by ELISA. rIL-10 (in the range 
of 0.1 to 250 ng/mL) shown the ability to inhibit the 
TNF-α production and to reduce MHC-II expression on 
stimulated BMDM. rIL-10 incorporation by NPs was 
confirmed by quantifying, the amount of rIL-10 in free 
in solution, that was negligible. In the presence of 20% 
serum, rIL-10 is being released over time in a BMDM 
culture. After two hours of incubation with the NPs/rIL-
10 complex, the rIL-10 reaches a maximum 
concentration; a stable value of about 35 ng/mL rIL-10 
being estimated after twenty-four hours. The rIL-10 
released from the NPs/rIL-10 complex was able to 
inhibit TNF-α production and MHC-II expression at the 
same level as the soluble rIL-10. 
DISCUSSION & CONCLUSIONS:  
IL-10 is a cytokine with a strong anti-inflammatory 
activity. A mutated form of murine IL-10 was 
successfully expressed in E. coli, recovered and purified 
from inclusion bodies. Its ability to reduce TNF-α 
synthesis and down-regulate MHCII molecules 
expression on activated BMDM was confirmed. Due to 
IL-10 potential applications in various medical fields, it 
is essential to develop systems that can effectively 
deliver the protein. For this purpose, dextrin NPs have 
been used and this work shows that dextrin NPs 
effectively incorporate IL-10 and enable the slow 
release of biologically active IL-10 over time. 
Altogether, these results demonstrate the suitability of 
dextrin NPs to be used as a system for the controlled 
release of IL-10. 
REFERENCES:1 R. de Waal Malefyt, et al (1991) J 
Exp Med 174:1209-20. 2 G. Gonçalves, et al (2007) 
Biomacromolecules 8:392-8. 
ACKNOWLEDGEMENTS: Vera Carvalho was 
supppoted by the grant SFRH/BD/27359/2006 from 
Fundação para a Ciência e Tecnologia (FCT), Portugal. 
This study was financially supported by FCT through 
the project PTDC/BIO/67160/2006. 
 
